Prostate Cancer Screening Remains Highly Debated
October 29th 2014While the USPSTF recommended against screening for prostate cancer, citing the high rate of false positives, complications from biopsy, and side-effects of aggressive treatment for a sometimes slowly-progressing disease, several medical organizations disagree.
Read More
AMA Expresses Concerns Over ONC Departures
October 28th 2014The American Medical Association voiced concerns over the fact that in addition to the departure of Karen. B. DeSalvo, MD, MPH, several other senior staff have recently left the Office of the National Coordinator for Health Information Technology.
Read More
Friction Between Health Plans, Pharma Grows Over Specialty Drugs
October 28th 2014The war of words between managed care and pharmaceutical manufacturers, which began when Gilead set the price for its drug to treat the hepatitis C virus (HCV), has taken off in October with the reclassification of a trio of cancer drugs from Genentech. Growth in the "specialty pharma" sector, where prices are rising much faster than drug prices generally, has drawn concern from payers and the umbrella group that represents them, while the trade group that represents drugmakers is pushing back against critics, saying that it faces challenges in bringing life-saving therapies to market.
Read More
Breakthrough Designation for Merck's Keytruda in NSCLC
October 27th 2014Recently approved as second-line treatment of metastatic melanoma, following resistance to ipilimumab, the FDA has now designated Keytruda as breakthrough therapy to treat EGFR-mutation and ALK-rearrangement negative NSCLC patients who have pr0gressed following platinum-based therapy.
Read More
Merck's Rapid Strides With Pembrolizumab
October 27th 2014Today, Merck announced that Keytruda has been granted breakthrough therapy designation for treating patients with epidermal growth factor receptor mutation-negative and anaplastic lymphoma kinase rearrangement-negative non-small cell lung cancer (NSCLC).
Read More
Ebola Vaccine Trials Move Forward, With Question of Who Pays Left Unanswered
October 27th 2014Trials to learn the safety of vaccines to prevent the spread of the Ebola virus are moving as fast as possible in the United States and in Great Britain, as public health officials on both sides of the Atlantic scramble to contain the worst-ever outbreak of the disease.
Read More
In the Literature: A Speech Gene Prevents Breast Cancer Metastasis
October 26th 2014The study, published in Cell Stem Cell, identified a microRNA-mediated inhibitory pathway that repressed expression of the speech and language gene FOXP2, promoting metastases of breast cancer cells to distant sites.
Read More
MIT Scientists Develop A Rapid Modeling Technique for Cancer Gene Mutations
October 25th 2014The group, led by Koch Institute director Tyler Jacks, used CRISPR to generate mutant genes that were then packaged into enteroviruses that were used to infect target organs in mice. This is a much faster process than the traditional method that need crossing genetically-engineered mice.
Read More
$840M Plan Unveiled to Boost Transitions to Outcome-Based Healthcare
October 24th 2014US Health and Human Services Secretary Sylvia M. Burwell announces new progams and financial incentives to help accountable care organizations (ACOs) and professional medical associations make the transition from fee-for-service to value-based healthcare delivery.
Read More
New Guiding Principles for Patient-Centered Care
October 23rd 2014Patient-centered care has been getting a lot of attention as the healthcare industry focuses on the Triple Aim of delivering better health outcomes, improving patient experience, and reducing the cost of care. In that vein, the Louis W. Sullivan Institute for Healthcare Innovation recently released 6 guiding principles of patient-centered care.
Read More